MVA BN YF
Alternative Names: MVA-BN Yellow Fever Vaccine; MVA-BN YF; Yellow fever vaccine-Bavarian NordicLatest Information Update: 31 Oct 2021
At a glance
- Originator Bavarian Nordic
- Developer Bavarian Nordic; National Institute of Allergy and Infectious Diseases
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Yellow fever
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for phase-I development in Yellow-fever(In volunteers) in USA (IM)
- 30 Mar 2018 National Institute of Allergy and Infectious Diseases completes a phase I trial in Yellow fever (In volunteers) in USA (IM) (NCT02743455)
- 01 May 2016 Phase-I clinical trials in Yellow fever (In volunteers) in USA (IM)